1. Home
  2. SASR vs CINGW Comparison

SASR vs CINGW Comparison

Compare SASR & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SASR
  • CINGW
  • Stock Information
  • Founded
  • SASR 1868
  • CINGW N/A
  • Country
  • SASR United States
  • CINGW United States
  • Employees
  • SASR N/A
  • CINGW 13
  • Industry
  • SASR Major Banks
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SASR Finance
  • CINGW Health Care
  • Exchange
  • SASR Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • SASR N/A
  • CINGW N/A
  • IPO Year
  • SASR 1996
  • CINGW 2021
  • Fundamental
  • Price
  • SASR N/A
  • CINGW $0.06
  • Analyst Decision
  • SASR Hold
  • CINGW
  • Analyst Count
  • SASR 3
  • CINGW 0
  • Target Price
  • SASR $29.33
  • CINGW N/A
  • AVG Volume (30 Days)
  • SASR 262.4K
  • CINGW N/A
  • Earning Date
  • SASR 04-22-2025
  • CINGW N/A
  • Dividend Yield
  • SASR 4.85%
  • CINGW N/A
  • EPS Growth
  • SASR N/A
  • CINGW N/A
  • EPS
  • SASR 0.44
  • CINGW N/A
  • Revenue
  • SASR $392,249,000.00
  • CINGW N/A
  • Revenue This Year
  • SASR $7.40
  • CINGW N/A
  • Revenue Next Year
  • SASR $28.03
  • CINGW N/A
  • P/E Ratio
  • SASR $62.73
  • CINGW N/A
  • Revenue Growth
  • SASR N/A
  • CINGW N/A
  • 52 Week Low
  • SASR $19.52
  • CINGW N/A
  • 52 Week High
  • SASR $39.55
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SASR 5.10
  • CINGW N/A
  • Support Level
  • SASR $28.60
  • CINGW N/A
  • Resistance Level
  • SASR $29.93
  • CINGW N/A
  • Average True Range (ATR)
  • SASR 0.67
  • CINGW 0.00
  • MACD
  • SASR -1.78
  • CINGW 0.00
  • Stochastic Oscillator
  • SASR 0.00
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: